| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6960577 | CHEPLAPHARM | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) | |
Zyprexa Zydis is owned by Cheplapharm.
Zyprexa Zydis contains Olanzapine.
Zyprexa Zydis has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Zyprexa Zydis are:
- US6960577
Zyprexa Zydis was authorised for market use on 06 April, 2000.
Zyprexa Zydis is available in tablet, orally disintegrating;oral dosage forms.
Zyprexa Zydis can be used as zyprexa zydis and fluoxetine in combination for the acute treatment of treatment resistant depression in adults.
The generics of Zyprexa Zydis are possible to be released after 01 November, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-591) | Mar 19, 2012 |
| Pediatric Exclusivity(PED) | Jun 04, 2013 |
| New Patient Population(NPP) | Dec 04, 2012 |
Drugs and Companies using OLANZAPINE ingredient
Market Authorisation Date: 06 April, 2000
Treatment: Zyprexa zydis and fluoxetine in combination for the acute treatment of treatment resistant depression in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
ZYPREXA ZYDIS family patents
